CIPLANSECipla Limited· PharmaceuticalsMinimalNeutral
Announced Wed, 13 May · 12:59 IST

Cipla Limited has informed the Exchange regarding a press release dated May 13, 2026.

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+10.9%1-day move
₹1293.70
prior close
₹1317.90
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+2.1+1.9+2.2+2.0+10.9+10.4+10.2+8.9+8.2+7.7+8.4+6.8+10.3
Up moveDown movePending
AI summary

Cipla Limited reported Q4 FY26 total income of INR 6,541 Cr, down 3% YoY from INR 6,730 Cr in Q4 FY25. EBITDA margin contracted to 15.2% from 22.8% YoY, while PAT fell to INR 555 Cr from INR 1,222 Cr in the same period last year. For the full year FY26, the company achieved its highest-ever annual revenue of INR 28,163 Cr, up 2% YoY, supported by strong One India business growth of 9% YoY reaching INR 12,680 Cr. North America revenue declined 13% YoY to $780 Mn, though the business received approval for its first AB-rated gVentolin with CGT from its US manufacturing facility. The company declared a final dividend of INR 13 per equity share (face value INR 2).

Likely market impact

While Cipla achieved record annual revenue, Q4 saw significant margin compression with PAT dropping over 50% YoY. North America weakness continues to weigh on performance, though strong India business and new product approvals provide some optimism. The healthy net cash position of INR 10,526 Cr offers financial flexibility.